Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?

Table 3

Multivariate backward regression analysis of factors explaining variability of the first tacrolimus trough level (model I) and multiple logistic regression predicting the risk of first tacrolimus trough level > 15 ng/ml (model II) in kidney transplant recipients. Both models included age, gender, BMI, pretransplant diabetes, hemoglobin, the presence of anti-HCV antibodies, and tacrolimus initial dose in mg/kg of body weight/day.

Independent variable	Model I		Model II
	± SD		OR (95% CI)
Age [per year]	0.105 ± 0,022	<0.001	1.02 (1.01–1.04)	0.003
BMI [per unit]	0.417 ± 0.082	<0.001	1.10 (1.05–1.16)	<0.001
Hemoglobin [per 1 g/dL]	0.607 ± 0.140	<0.001	1.25 (1.12–1.40)	<0.001
Anti-HCV positive	4.942 ± 1.024	<0.001	3.22 (1.64–6.31)	<0.001
Tacrolimus dose [per 1 mg/kg/day]	16.457 ± 9.321	0.08	-

SD: standard deviation, OR: odds ratio, BMI: body mass index, and HCV: hepatitis C virus. Statistics: values below 0.05 were considered statistically significant, and value between 0.05 and 0.1 was interpreted as borderline significant.